Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0P2ZY
|
||||
| Former ID |
DNCL002226
|
||||
| Drug Name |
INNO-305
|
||||
| Indication | Acute myeloid leukemia; Lung cancer [ICD9: 205, 162; ICD10:C92.0, C33-C34] | Phase 1 | [1] | ||
| Company |
CytRx
|
||||
| Target and Pathway | |||||
| Target(s) | Wilms' tumor protein | Target Info | Modulator | [2] | |
| KEGG Pathway | Transcriptional misregulation in cancer | ||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| Regulation of Telomerase | |||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Integrated Pancreatic Cancer Pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753) | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.